Idiopathic Pulmonary Fibrosis (IPF): An Overview Shaney L. Barratt 1,2,*, Andrew Creamer 1, Conal Hayton 3 and Nazia Chaudhuri 3 1 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK;andrew.creamer@nbt.nhs.uk2 Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK3 North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, […]
Tag: Nintedanib
Recent Posts
- This PF Awareness Month, Action for Pulmonary Fibrosis is asking everyone to Take Action for PF.
- Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction
- September is Pulmonary Fibrosis Awareness Month
- The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis
- Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
- September is Pulmonary Fibrosis (PF) Awareness Month
- Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
- Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
- Plasticity towards Rigidity: A Macrophage Conundrum in
Pulmonary Fibrosis - TIPAL
- Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
- Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
- Mitochondrial Quality Control in COPD and IPF
- Idiopathic Pulmonary Fibrosis (IPF): An Overview
- UK Petition, March 2023
- Pulmonary Fibrosis Research and Education Hub
- Hello world!
Recent Comments
No comments to show.